跳至主要内容
临床试验/ACTRN12616000025437
ACTRN12616000025437尚未招募4 期

A randomised controlled trial of Rebuilding the lEft anterior deScending artery for LIMA grafTing with biO-ReabsorbablE scaffolds versus conventional management.

The University of Western Australia0 个研究点目标入组 30 人开始时间: 2016年1月15日最近更新:
适应症

试验速览

阶段
4 期
状态
尚未招募
入组人数
30

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomised controlled trial
主要目的
Treatment
盲法
Blinded (masking used)

入排标准

年龄范围
18 Years 至 70 Years(—)
性别
All

入选标准

  • 1. Diffuse LAD disease greater than or equal 50mm in length that is not attractive for surgical revascularisation due to LAD anatomy as judged by a cardiothoracic surgeon.
  • 2. Reconstruction of the LAD with BRS is technically feasible as judged by an experienced BRS implanter.
  • 3. Preserved antero-apical wall motion

排除标准

  • 1. Reconstruction of the LAD with BVS is not technically feasible due to deliverability.
  • 2. Significally impaired LV systolic function of the anterior wall without demonstrable ischaemia (FFR <0.80 or moderate to large reversible perfusion defect on ischameia testing in the LAD territory)
  • 3. Unable or unlikely to take or tolerate long term DAPT
  • 4. Intolerance to Everolimus
  • 5. Unlikely to survive the duration of the study due to othe comorbidity
  • 6. Advanced renal disease not on haemodialysis (eGFR <30ml/min)
  • 7. Within 48 hour of STEMI
  • 8. Prior revascularisation of the mid to distal LAD with stents or CABG.

研究者

相似试验